Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of MS consistent with locally labeled indication for DMF
No prior treatment with DMF
Female subjects of childbearing potential who are not surgically sterile and male subjects must practice effective contraception during their participation in the study
Have had a recent complete blood count (CBC), including lymphocyte count, that does not preclude participation in the study, in the judgement of the investigator
You may not be if
Have a recent history or ongoing GI illness (e.g., peptic ulcer, irritable bowel syndrome) or any other current condition with GI signs and symptoms (e.g., nausea, vomiting, abdominal pain, or diarrhea) that may interfere with assessment of study endpoints
Have other major comorbid conditions that preclude participation in the study, as determined by the investigator
Participant is pregnant, breastfeeding, or planning a pregnancy during the study period
Are receiving concomitant disease-modifying therapies for MS including, but not limited to, natalizumab, interferon beta, glatiramer acetate, fingolimod, alemtuzumab, teriflunomide, or laquinimod at screening
History of severe allergic or anaphylactic reactions or known drug hypersensitivity
